MBX Biosciences Completes STEADI Trial, Putting Imapextide on Investors’ Radar

MBX's Flagship Drug Trial Met Expectations But Perhaps Some Investors Wanted More -- Market Talk

Analysts’ Top Healthcare Picks: MBX Biosciences, Inc. (MBX), Kura Oncology (KURA)

Shares of Mbx Biosciences Fall 9.9% After Cos Hormone Disorder Drug Data Fall Short of Expectations

MBX Biosciences' Phase 2 Trial of Canvuparatide Meets Primary Endpoint; Shares Drop Pre-Bell

BUZZ-MBX Biosciences reports one-year data for hormone disorder drug, shares fall

MBX Biosciences posts ENDO 2026 canvuparatide presentation update

MBX Biosciences announces results from Avail, canvuparatide trials

BRIEF-Mbx Biosciences Announces One-Year Data Demonstrating Sustained Benefit Of Once-Weekly Canvuparatide As A Potential Pth Replacement Therapy In Chronic Hypoparathyroidism

MBX Biosciences says Phase 2 data show once-weekly canvuparatide sustains 57% responder rate at one year in hypoparathyroidism

Mbx Biosciences - 90% of Patients in Ole Remained in Study at One Year

Mbx Biosciences - Canvuparatide Well Tolerated With No New Safety Signals During One-Year Ole

Mbx Biosciences - Responder Rate 57% at One Year Ole, 63% at 12 Weeks Phase 2 Avail Trial

Mbx Biosciences - Phase 3 Pivotal Trial for Canvuparatide on Track to Initiate in Q3 2026

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), MBX Biosciences, Inc. (MBX) and GoodRx Holdings (GDRX)

Analysts Offer Insights on Healthcare Companies: Artiva Biotherapeutics, Inc. (ARTV), MoonLake Immunotherapeutics (MLTX) and MBX Biosciences, Inc. (MBX)

MBX Biosciences Shareholders Approve Directors and Auditor

MBX Biosciences shareholders elect Patrick Heron, Edward Mathers as Class II directors

Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (LQDA) and MBX Biosciences, Inc. (MBX)